Seroprevalence of hepatitis B and hepatitis C in people who inject drugs and other high risk groups in a tertiary care hospital in Northeast India

Arup Roy, Praveen Sh, Kh Sulochana Devi, Paotinlal Haokip, Gracy Laldinmawii, S. Damrolien


Background: Viral hepatitis is a serious public health problem affecting billions of people globally. The Hepatitis B virus (HBV) and Hepatitis C virus (HCV) are blood borne pathogens, frequently causing deaths among general and various high risk populations. This study was carried out with the aim to determine the seroprevalence of HBV and HCV in people who inject drugs (PWID) and other risk groups.

Methods: A cross-sectional study carried out in the Dept. of Microbiology, RIMS, Imphal from October 2014 to September 2016. 103 high risk individuals, including PWID, spouse of high risk people, unprotected sex with female sex worker (FSW), multiple partners (MP), men having sex with men (MSM) and needle prick injuries were included in this study. Serum samples were tested using Enzyme linked immunosorbent assay (ELISA).

Results: Out of 103 cases, 87.4% were males and 12.6% females. PWID comprised of 49.5%. Seroprevalence of HBV was 17.4%, anti HBc IgG 16.5% and anti HBc IgM 0.9%. Seroprevalence of HCV was 41.7%, anti HCV IgG 39.8% and anti HCV IgM 1.9%. The rate of HBV and HCV coinfection was 9.7%. Among the PWID seroprevalence of HBV and HCV was 17.6% and 64.7% respectively.

Conclusions: This study determines the current status of acute and chronic infection with HBV and HCV in high risk populations. Anti HBc IgG & IgM and anti HCV IgG and IgM are sensitive epidemiological markers to determine the burden of the disease. 


HBV, HCV, PWID, Coinfection

Full Text:



Lavanchy D. Hepatitis B, virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107.

Cindy M, Ian W, Eric E, Susan AW, Lyn F, Wasley A, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR 2008;57:1–28.

Andre F. Hepatitis B epidemiology in Asia, the Middle East and Africa. Pub Med. 2000;18(1):20–22.

Liu Z, Hou J. Hepatitis B virus and hepatitis C virus dual infection. Int J Med Sci. 2006;3(2):57– 62.

Huo T, Huang Y, Hsia C, Su C, Lin H, Hsu C, et al. Characteristics and outcome of patients with dual hepatitis B and C associated hepatocellular carcinoma: Are they different from patients with single virus infection. Liver Int. 2009;5:767–73.

Batham A, Narula D, Toteja T, Sreenivas V, Puliyel JM. Systematic review and meta-analysis of prevalence of Hepatitis B in India. Indian Pediatr. 2007;44:663-74.

Kumar M, Sarin SK. Viral hepatitis eradication in India by 2080- gaps, challenges and targets. Indian J Med Res. 2014;140:1-4.

Acharya SK. Hepatology in India. Sailing without a mast. Trop Gastroenterol 1999;20:145.

Beyrer C, Razak MH, Lisam K, Chen J, Lui W, Yu XF. Overland heroin trafficking routes and HIV-1 spread in south and south-east Asia. AIDS. 2000;14:75–83.

National AIDS Control Organization. State fact sheets 2014. Available at state fact sheets/. Accessed on 6 January 2016.

Devi KS, Singh NB, Mara J, Singh TB, Singh YM. Seroprevalence of hepatitis B virus and hepatitis C virus among hepatic disorders and injecting drug users in Manipur. A preliminary report. Indian J Med Micribiol. 2004;22:136-37.

Saravanan S, Velu V, Nandakumar S, Madhavan V, Uma S, Kailapuri G, et al. Hepatitis B virus and hepatitis C virus dual infection among patients with chronic liver disease. J Microbiol Immunol Infect. 2009;42:122-8.

Maheswari KS, Arun R, Arumugam P. The prevalence of the hepatitis B core antibody and the occult hepatitis B infection among voluntary blood donors in Chennai, India. J Clin Diagn Res. 2012;6(10):1710-2.

Sood S. Serological evaluation of hepatitis B virus in outpatient department patients of a private hospital in North-west India. National J Community Med. 2013;4:485-8.

Mahajan P, Singh M, Garg A, Garg PD, Singh P. Prevalence of hepatitis C viral infection among opioid dependent injectable drug users: A study conducted at Swami Vivekananda drug de-addiction and treatment centre, Amritsar. J Dual Diagn. 2016;1(2):6-8.

Kermode M, Nuken A, Medhi GM, Akoijam BS, Sharma H, Mahanta J. High burden of hepatitis C & HIV co-infection among people who inject drugs in Manipur, Northeast India. Indian J Med Res. 2016;143:348-56.

Ray S, Sarna A, Sebastian MP, Sharma V, Madan I, Thior I, et al. HIV, HBV HCV among people who inject drugs: High prevalence of HIV and HCV RNA positive infections observed in Delhi, India. BMC Public Health. 2015;15:726-32.

Singh V, Katyal R, Kochhar RK, Bhasin DK, Aggarwal RP. Study of hepatitis B and C viral markers in patients of chronic liver disease. Indian J Med Microbiol. 2004;22(4):269-70.

Javadi A, Ataei B, Kassaian N, Nokhodian Z, Majid Y. Co-infection of human immunodeficiency virus, hepatitis C and hepatitis B virus among injection drug users in drop in centers. J Res Med Sci. 2014;19(1):17–21.